{"id":"radium","rwe":[{"pmid":"41903088","year":"2026","title":"Clinical efficacy of radium-223 in simulating real-world clinical practice: a meta-analysis.","finding":"","journal":"Annals of nuclear medicine","studyType":"Clinical Study"},{"pmid":"41895479","year":"2026","title":"Executive Summary of the American Radium Society® (ARS) Appropriate Use Criteria (AUC) for Selective Use of Pelvic Radiotherapy in Locally-Advanced Rectal Cancer: A Consensus Statement.","finding":"","journal":"International journal of radiation oncology, biology, physics","studyType":"Clinical Study"},{"pmid":"41893461","year":"2026","title":"A Comprehensive Study on Radiological Hazard Assessment and Geological Features of Gypsum Deposits.","finding":"","journal":"Toxics","studyType":"Clinical Study"},{"pmid":"41892523","year":"2026","title":"Alkali-Activated Materials from Diverse Solid Precursors: Structural, Mechanical and Radiological Properties.","finding":"","journal":"Gels (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41882248","year":"2026","title":"Assessment of levels spatiotemporal differences and health risks of environmental radioactivity in the soil of Chongqing China.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Oral","category":"route"},{"label":"Solution","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Bayer Hlthcare","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Bayer Hlthcare","patents":[],"pricing":[],"allNames":"radium bromatum","offLabel":[],"synonyms":["Radium bromatum","RADIUM BROMIDE"],"timeline":[{"date":"20160429","type":"positive","source":"OpenFDA","milestone":"FDA approval (Bayer Hlthcare)"}],"approvals":[{"date":"20160429","orphan":false,"company":"BAYER HLTHCARE","regulator":"FDA"}],"brandName":"Radium bromatum","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells are like a city with a mayor. Cancer cells are like a corrupt mayor who makes bad decisions and causes problems. Radium bromatum is like a special kind of police officer that uses radiation to arrest the corrupt mayor and restore order to the city.","oneSentence":"Radium bromatum works by emitting ionizing radiation that damages cancer cells, preventing them from growing and dividing.","technicalDetail":"Radium bromatum is a radioactive isotope that emits alpha particles, which cause double-strand DNA breaks in cancer cells, leading to cell death and inhibition of tumor growth."},"commercial":{"launchDate":"2016","_launchSource":"OpenFDA (20160429, BAYER HLTHCARE)"},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"RADIUM\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:\"RADIUM\"","fields":["approvals","company"],"source":"OpenFDA Drugs@FDA"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=radium","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=radium","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:27:21.258736","biosimilars":[],"competitors":[],"genericName":"radium","indications":{"approved":[{"name":"Malignant tumor of prostate","diseaseId":"malignant-tumor-of-prostate","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"Bayer Hlthcare","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT04090398","phase":"PHASE2","title":"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-04","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic HER2-Negative Breast Carcinoma","Metastatic Malignant Neoplasm in the Bone"],"enrollment":70,"completionDate":"2026-06-30"},{"nctId":"NCT04071236","phase":"PHASE1,PHASE2","title":"Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-10-14","conditions":["Metastatic Castration-Resistant Prostate Carcinoma","Metastatic Malignant Neoplasm in the Bone","Metastatic Malignant Neoplasm in the Lymph Nodes","Stage IVB Prostate Cancer AJCC v8"],"enrollment":90,"completionDate":"2026-04-30"},{"nctId":"NCT04071223","phase":"PHASE2","title":"Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-29","conditions":["Advanced Renal Cell Carcinoma","Chromophobe Renal Cell Carcinoma","Clear Cell Renal Cell Carcinoma","Collecting Duct Carcinoma","Kidney Medullary Carcinoma","Metastatic Malignant Neoplasm in the Bone","Papillary Renal Cell Carcinoma","Stage IV Renal Cell Cancer AJCC v8","Unclassified Renal Cell Carcinoma"],"enrollment":134,"completionDate":"2026-10-01"},{"nctId":"NCT06401980","phase":"PHASE2","title":"Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2024-10-22","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":162,"completionDate":"2030-09"},{"nctId":"NCT04109729","phase":"PHASE1","title":"Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2020-09-16","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":39,"completionDate":"2026-04-30"},{"nctId":"NCT04597125","phase":"PHASE4","title":"RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2020-11-09","conditions":["Metastatic Castrate Resistant Prostate Cancer (mCRPC)"],"enrollment":654,"completionDate":"2026-10-12"},{"nctId":"NCT03344211","phase":"PHASE2","title":"Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2018-11-21","conditions":["Castration-Resistant Prostate Carcinoma","Prostate Carcinoma Metastatic in the Bone","Stage IV Prostate Cancer"],"enrollment":30,"completionDate":"2027-11-21"},{"nctId":"NCT00699751","phase":"PHASE3","title":"A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06-12","conditions":["Hormone Refractory Prostate Cancer","Bone Metastases"],"enrollment":921,"completionDate":"2014-02-13"},{"nctId":"NCT03317392","phase":"PHASE1,PHASE2","title":"Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-04","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":145,"completionDate":"2027-02-16"},{"nctId":"NCT04489719","phase":"","title":"Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2021-04-16","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Malignant Neoplasm in the Bone","Metastatic Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":48,"completionDate":"2029-08-01"},{"nctId":"NCT05133440","phase":"PHASE2","title":"A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-11-12","conditions":["Prostate Cancer"],"enrollment":12,"completionDate":"2027-11-12"},{"nctId":"NCT05924672","phase":"PHASE2","title":"Efficacy of Ra-223 in PSMA PET Optimally Selected Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-08-30","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Malignant Neoplasm in the Bone","Stage IVB Prostate Cancer AJCC v8"],"enrollment":2,"completionDate":"2027-03-31"},{"nctId":"NCT02141438","phase":"","title":"Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-08-20","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":1472,"completionDate":"2024-10-24"},{"nctId":"NCT03737370","phase":"PHASE1","title":"Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2018-01-30","conditions":["Metastatic Castrate Resistant Prostate Cancer"],"enrollment":43,"completionDate":"2025-09-30"},{"nctId":"NCT02194842","phase":"PHASE3","title":"Phase III Radium 223 mCRPC-PEACE III","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2015-10","conditions":["Prostate Cancer"],"enrollment":446,"completionDate":"2028-12"},{"nctId":"NCT04521361","phase":"PHASE1","title":"A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-11-16","conditions":["Bone Metastatic Castration-resistant Prostate Cancer"],"enrollment":46,"completionDate":"2025-08-27"},{"nctId":"NCT02803437","phase":"","title":"Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-07-21","conditions":["Prostatic Neoplasms, Castration-Resistant"],"enrollment":334,"completionDate":"2024-12-18"},{"nctId":"NCT06659926","phase":"NA","title":"The Radium-select Study","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2025-02-24","conditions":["mCRPC","Male Urogenital Diseases"],"enrollment":60,"completionDate":"2029-07-01"},{"nctId":"NCT03361735","phase":"PHASE2","title":"Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-08-29","conditions":["Prostate Adenocarcinoma"],"enrollment":25,"completionDate":"2026-02-04"},{"nctId":"NCT03304418","phase":"PHASE2","title":"Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone","status":"COMPLETED","sponsor":"University of Utah","startDate":"2018-02-27","conditions":["Prostate Cancer Metastatic to Bone"],"enrollment":20,"completionDate":"2023-08-31"},{"nctId":"NCT03076203","phase":"PHASE1","title":"Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2017-09-22","conditions":["Prostate Carcinoma Metastatic to the Bone","Stage IV Prostate Adenocarcinoma","Hormone-refractory Prostate Cancer"],"enrollment":14,"completionDate":"2022-11-07"},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)","Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"],"enrollment":750,"completionDate":"2026-12"},{"nctId":"NCT03753776","phase":"PHASE3","title":"Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2019-07-15","conditions":["Breast Cancer"],"enrollment":232,"completionDate":"2024-04-05"},{"nctId":"NCT03093428","phase":"PHASE2","title":"Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-06-09","conditions":["Prostate Cancer"],"enrollment":45,"completionDate":"2025-02-28"},{"nctId":"NCT02043678","phase":"PHASE3","title":"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-30","conditions":["Prostatic Neoplasms"],"enrollment":806,"completionDate":"2024-02-08"},{"nctId":"NCT03002220","phase":"PHASE2","title":"Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status","status":"COMPLETED","sponsor":"MedSIR","startDate":"2016-12-21","conditions":["Prostate Cancer"],"enrollment":52,"completionDate":"2021-06-09"},{"nctId":"NCT03996473","phase":"PHASE1","title":"Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases","status":"TERMINATED","sponsor":"Bayer","startDate":"2020-03-06","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":8,"completionDate":"2023-01-30"},{"nctId":"NCT04232761","phase":"","title":"Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-07-07","conditions":["Castration-resistant Prostate Cancer"],"enrollment":194,"completionDate":"2024-04-29"},{"nctId":"NCT04587427","phase":"","title":"A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-05-15","conditions":["Bone Metastatic Castration-resistant Prostate Cancer"],"enrollment":1067,"completionDate":"2023-05-30"},{"nctId":"NCT03315260","phase":"","title":"Treatment Satisfaction With Ra-223 in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-04-11","conditions":["Prostatic Neoplasms"],"enrollment":85,"completionDate":"2023-03-20"},{"nctId":"NCT02903160","phase":"PHASE2","title":"Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2017-01-13","conditions":["Prostate Cancer"],"enrollment":40,"completionDate":"2021-11-15"},{"nctId":"NCT04256993","phase":"","title":"PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-02-15","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"enrollment":1434,"completionDate":"2021-06-01"},{"nctId":"NCT02258451","phase":"PHASE2","title":"Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-04","conditions":["Breast Neoplasms"],"enrollment":283,"completionDate":"2022-10-28"},{"nctId":"NCT00337155","phase":"PHASE2","title":"BAY88-8223, Dose Finding Study in Patients With HRPC","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-05","conditions":["Prostate Cancer","Neoplasm Metastasis"],"enrollment":122,"completionDate":"2009-12"},{"nctId":"NCT04681144","phase":"","title":"A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-04-08","conditions":["Prostate Cancer"],"enrollment":103,"completionDate":"2022-11-21"},{"nctId":"NCT05301062","phase":"","title":"A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels","status":"TERMINATED","sponsor":"Bayer","startDate":"2022-09-15","conditions":["Metastatic Castration-resistant Prostate Cancer","Bone Metastases"],"enrollment":8,"completionDate":"2023-06-30"},{"nctId":"NCT05771896","phase":"PHASE3","title":"Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC","status":"WITHDRAWN","sponsor":"GenesisCare USA","startDate":"2023-09","conditions":["Metastatic Prostate Cancer"],"enrollment":0,"completionDate":"2029-04"},{"nctId":"NCT00667199","phase":"PHASE2","title":"BAY88-8223, Does Response Study in HRPC Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-05-30","conditions":["Hormone Refractory Prostate Cancer","Bone Metastases"],"enrollment":100,"completionDate":"2009-10-06"},{"nctId":"NCT02278055","phase":"PHASE2","title":"Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-10-08","conditions":["Metastatic Prostate Cancer","Pain"],"enrollment":29,"completionDate":"2022-02-02"},{"nctId":"NCT03247010","phase":"","title":"Bone Marrow Suppression and Recovery During Radionuclide Treatment","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2017-06-20","conditions":["Castration-resistant Prostate Cancer"],"enrollment":68,"completionDate":"2020-10-01"},{"nctId":"NCT04237584","phase":"PHASE3","title":"A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients","status":"TERMINATED","sponsor":"MANA RBM","startDate":"2020-06-30","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":23,"completionDate":"2022-03-07"},{"nctId":"NCT02346526","phase":"PHASE2","title":"A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-04","conditions":["Prostate Cancer","Castration-resistant Prostate Cancer","Castration-resistant Prostate Cancer Metastatic to Bone"],"enrollment":22,"completionDate":"2020-12"},{"nctId":"NCT02582749","phase":"PHASE2","title":"Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases","status":"TERMINATED","sponsor":"Ajjai Alva, MD","startDate":"2016-04","conditions":["Prostate Cancer","Bone Metastases","Prostate Neoplasms"],"enrollment":16,"completionDate":"2017-09-14"},{"nctId":"NCT04281147","phase":"","title":"Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-02-24","conditions":["Prostate Cancer"],"enrollment":4301,"completionDate":"2021-06-22"},{"nctId":"NCT03223597","phase":"","title":"Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2015-01-17","conditions":["Prostate Cancer Metastatic","Bone Metastases"],"enrollment":300,"completionDate":"2018-03-01"},{"nctId":"NCT04516161","phase":"","title":"EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-08-03","conditions":["Metastatic Castration Resistant Prostate Cancer (mCRPC)"],"enrollment":1180,"completionDate":"2021-03-31"},{"nctId":"NCT02135484","phase":"NA","title":"Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-09-19","conditions":["Prostate Cancer"],"enrollment":27,"completionDate":"2020-11-11"},{"nctId":"NCT03896984","phase":"","title":"Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-03-18","conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)"],"enrollment":346,"completionDate":"2020-12-14"},{"nctId":"NCT02450812","phase":"","title":"Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-05-28","conditions":["Prostatic Neoplasms, Castration-Resistant"],"enrollment":86,"completionDate":"2020-09-17"},{"nctId":"NCT02398526","phase":"","title":"Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-03-19","conditions":["Castration-Resistant Prostatic Cancer"],"enrollment":363,"completionDate":"2020-07-15"},{"nctId":"NCT02366130","phase":"PHASE2","title":"Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-02-11","conditions":["Breast Cancer"],"enrollment":45,"completionDate":"2020-12-16"},{"nctId":"NCT03062254","phase":"PHASE2","title":"Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy","status":"COMPLETED","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2018-03-22","conditions":["Prostate Cancer"],"enrollment":14,"completionDate":"2021-07-15"},{"nctId":"NCT04995614","phase":"","title":"Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2017-04-01","conditions":["Castrate Resistant Prostate Cancer","Bone Metastases"],"enrollment":122,"completionDate":"2020-06-29"},{"nctId":"NCT02113384","phase":"","title":"Locally Advanced Rectal Cancer - Exfoliated Peritoneal Tumor Cells","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2012-09","conditions":["Rectal Cancer"],"enrollment":231,"completionDate":"2028-01"},{"nctId":"NCT02463799","phase":"PHASE2","title":"Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-02-22","conditions":["Prostate Cancer"],"enrollment":36,"completionDate":"2019-12-12"},{"nctId":"NCT02981797","phase":"","title":"Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2015-07-22","conditions":["Prostate Cancer","Prostate Adenocarcinoma"],"enrollment":10,"completionDate":"2020-11-05"},{"nctId":"NCT02283749","phase":"PHASE2","title":"BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases","status":"COMPLETED","sponsor":"Angela Taber MD","startDate":"2015-09","conditions":["Non Small Cell Lung Cancer With Bone Metastatses"],"enrollment":5,"completionDate":"2018-11-13"},{"nctId":"NCT03458559","phase":"PHASE3","title":"Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2018-05-16","conditions":["Prostate Cancer Metastatic to Bone"],"enrollment":402,"completionDate":"2024-05-16"},{"nctId":"NCT02199197","phase":"PHASE2","title":"Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-06-25","conditions":["Prostate Cancer"],"enrollment":49,"completionDate":"2019-10-03"},{"nctId":"NCT03419442","phase":"","title":"Multi-academic Center Study of Xofigo Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-12-03","conditions":["Prostate Cancer, Castration Resistant"],"enrollment":150,"completionDate":"2019-10-22"},{"nctId":"NCT02258464","phase":"PHASE2","title":"Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Bayer","startDate":"2015-03-02","conditions":["Breast Neoplasms"],"enrollment":99,"completionDate":"2019-08-13"},{"nctId":"NCT03563014","phase":"","title":"A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-07-31","conditions":["Prostatic Neoplasms, Castration-Resistant"],"enrollment":164,"completionDate":"2019-01-31"},{"nctId":"NCT02899104","phase":"","title":"Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-06-15","conditions":["Prostatic Neoplasms, Castration-Resistant"],"enrollment":200,"completionDate":"2019-03-31"},{"nctId":"NCT02406521","phase":"PHASE1","title":"Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-04","conditions":["Metastatic Renal Cell Carcinoma"],"enrollment":30,"completionDate":"2019-12-31"},{"nctId":"NCT02928029","phase":"PHASE1,PHASE2","title":"Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"Bayer","startDate":"2017-02-10","conditions":["Multiple Myeloma"],"enrollment":7,"completionDate":"2019-03-20"},{"nctId":"NCT02925702","phase":"","title":"PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.","status":"UNKNOWN","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2016-02","conditions":["Advanced Prostate Cancer","Castration Resistant","Radium 223"],"enrollment":161,"completionDate":"2020-09"},{"nctId":"NCT04110782","phase":"","title":"Radical Prostatectomy and External Beam Radiotherapy in mCRPC With 223Radium-dicloride (RaProRad)","status":"UNKNOWN","sponsor":"Azienda Policlinico Umberto I","startDate":"2015-09","conditions":["Prostate Cancer"],"enrollment":400,"completionDate":"2020-01"},{"nctId":"NCT02814669","phase":"PHASE1","title":"Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-09-23","conditions":["Castrate-Resistant Prostate Cancer"],"enrollment":45,"completionDate":"2019-07-31"},{"nctId":"NCT02034552","phase":"PHASE2","title":"A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-07","conditions":["Prostatic Neoplasms"],"enrollment":68,"completionDate":"2018-06-26"},{"nctId":"NCT02023697","phase":"PHASE2","title":"Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-10","conditions":["Prostatic Neoplasms"],"enrollment":391,"completionDate":"2018-08-09"},{"nctId":"NCT03368989","phase":"","title":"The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2014-02-11","conditions":["Bony Metastases From Castrate Refractory Prostate Cancer"],"enrollment":21,"completionDate":"2017-02-07"},{"nctId":"NCT02390934","phase":"PHASE2","title":"Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2014-10-01","conditions":["Thyroid Cancer"],"enrollment":13,"completionDate":"2019-04-02"},{"nctId":"NCT02507570","phase":"PHASE2","title":"Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis","status":"COMPLETED","sponsor":"Carolina Research Professionals, LLC","startDate":"2015-09-23","conditions":["Prostate Carcinoma Metastatic to the Bone"],"enrollment":40,"completionDate":"2019-01-18"},{"nctId":"NCT03414437","phase":"","title":"Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)","status":"UNKNOWN","sponsor":"Carolina Research Professionals, LLC","startDate":"2017-10-01","conditions":["Prostate Cancer Metastatic"],"enrollment":31,"completionDate":"2021-10-01"},{"nctId":"NCT03325127","phase":"","title":"Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2017-10-30","conditions":["Prostatic Neoplasms, Castration-Resistant"],"enrollment":0,"completionDate":"2018-09-28"},{"nctId":"NCT01810770","phase":"PHASE3","title":"Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-03-26","conditions":["Prostatic Neoplasms"],"enrollment":243,"completionDate":"2017-09-25"},{"nctId":"NCT02518698","phase":"","title":"Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-08-31","conditions":["Prostate Cancer"],"enrollment":1163,"completionDate":"2017-09-30"},{"nctId":"NCT01929655","phase":"PHASE2","title":"Japanese BAY88-8223 Monotherapy Phase II Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-09-30","conditions":["Prostatic Neoplasms"],"enrollment":49,"completionDate":"2017-05-16"},{"nctId":"NCT01934790","phase":"PHASE1,PHASE2","title":"Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-12-22","conditions":["Prostatic Neoplasms"],"enrollment":45,"completionDate":"2017-04-12"},{"nctId":"NCT02097303","phase":"PHASE2","title":"Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis","status":"COMPLETED","sponsor":"Carolina Research Professionals, LLC","startDate":"2014-03","conditions":["Prostate Cancer"],"enrollment":36,"completionDate":"2015-12"},{"nctId":"NCT02729103","phase":"","title":"Treatment Patterns in Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-10-31","conditions":["Prostatic Neoplasm"],"enrollment":565,"completionDate":"2017-01-19"},{"nctId":"NCT02331303","phase":"","title":"A Drug Utilization Study of Radium-223 in Sweden","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-04-15","conditions":["Neoplasms"],"enrollment":37,"completionDate":"2017-12-19"},{"nctId":"NCT02429804","phase":"PHASE1","title":"NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Stanford University","startDate":"2015-04","conditions":["Hormone-Resistant Prostate Cancer","Metastatic Malignant Neoplasm in the Bone","Metastatic Prostate Carcinoma"],"enrollment":4,"completionDate":"2017-05-15"},{"nctId":"NCT01798108","phase":"PHASE1","title":"Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2001-08-14","conditions":["Neoplasm Metastasis"],"enrollment":31,"completionDate":"2003-06-25"},{"nctId":"NCT01618370","phase":"PHASE3","title":"Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-07-22","conditions":["Prostatic Neoplasms"],"enrollment":705,"completionDate":"2016-02-28"},{"nctId":"NCT01106352","phase":"PHASE1,PHASE2","title":"A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-07","conditions":["Bone Metastases","Castration-Resistant Prostate Cancer"],"enrollment":70,"completionDate":"2015-06"},{"nctId":"NCT02442063","phase":"PHASE1","title":"Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-08","conditions":["Neoplasms","Bone Diseases"],"enrollment":15,"completionDate":"2016-10"},{"nctId":"NCT02880943","phase":"PHASE1,PHASE2","title":"Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)","status":"UNKNOWN","sponsor":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","startDate":"2016-10","conditions":["Clear-cell Metastatic Renal Cell Carcinoma","Bone Metastases"],"enrollment":42,"completionDate":"2021-02"},{"nctId":"NCT01565746","phase":"PHASE1","title":"Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-03","conditions":["Prostatic Neoplasms"],"enrollment":19,"completionDate":"2016-04"},{"nctId":"NCT02656563","phase":"PHASE2","title":"Radium 223 Following Intermittent ADT","status":"WITHDRAWN","sponsor":"Canadian Urology Research Consortium","startDate":"2015-10","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":"2020-10"},{"nctId":"NCT02605356","phase":"PHASE1,PHASE2","title":"Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2016-10","conditions":["Multiple Myeloma"],"enrollment":0,"completionDate":"2021-07"},{"nctId":"NCT02484339","phase":"PHASE2","title":"Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)","status":"UNKNOWN","sponsor":"University Hospital Freiburg","startDate":"2014-12","conditions":["Prostate Carcinoma"],"enrollment":274,"completionDate":"2017-12"},{"nctId":"NCT00667537","phase":"PHASE1","title":"PK in Pts With HRPC & Skeletal Metastes","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-07","conditions":["Prostatic Neoplasms"],"enrollment":6,"completionDate":"2008-12"},{"nctId":"NCT02396368","phase":"PHASE1","title":"A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-03","conditions":["Prostate Cancer","Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)"],"enrollment":0,"completionDate":"2017-07"},{"nctId":"NCT01516762","phase":"","title":"Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases","status":"NO_LONGER_AVAILABLE","sponsor":"Bayer","startDate":"","conditions":["Prostatic Neoplasms"],"enrollment":0,"completionDate":""},{"nctId":"NCT01070485","phase":"PHASE2","title":"BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-01","conditions":["Breast Cancer","Bone Metastases"],"enrollment":23,"completionDate":"2012-01"},{"nctId":"NCT00459654","phase":"PHASE2","title":"A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-02","conditions":["Prostate Cancer","Neoplasm Metastasis"],"enrollment":64,"completionDate":"2007-05"},{"nctId":"NCT00748046","phase":"PHASE1","title":"Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-08","conditions":["Prostate Cancer","Metastases","Pharmacokinetics"],"enrollment":10,"completionDate":"2009-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Solution","formulations":[{"form":"SOLUTION","route":"ORAL","productName":""}]},"_patentsChecked":true,"crossReferences":{"UNII":"R74O7T8569","SPL_ID":"28d8b606-37ac-642c-e063-6294a90ad080"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"2016-","companyName":"Bayer Hlthcare","relationship":"Original Developer"}],"publicationCount":7713,"therapeuticAreas":["Oncology"],"applicationNumber":"NDA203971","biosimilarFilings":[],"originalDeveloper":"Bayer Hlthcare","recentPublications":[{"date":"2026 Mar 28","pmid":"41903088","title":"Clinical efficacy of radium-223 in simulating real-world clinical practice: a meta-analysis.","journal":"Annals of nuclear medicine"},{"date":"2026 Mar 25","pmid":"41895479","title":"Executive Summary of the American Radium Society® (ARS) Appropriate Use Criteria (AUC) for Selective Use of Pelvic Radiotherapy in Locally-Advanced Rectal Cancer: A Consensus Statement.","journal":"International journal of radiation oncology, biology, physics"},{"date":"2026 Feb 25","pmid":"41893461","title":"A Comprehensive Study on Radiological Hazard Assessment and Geological Features of Gypsum Deposits.","journal":"Toxics"},{"date":"2026 Feb 27","pmid":"41892523","title":"Alkali-Activated Materials from Diverse Solid Precursors: Structural, Mechanical and Radiological Properties.","journal":"Gels (Basel, Switzerland)"},{"date":"2026 Mar 25","pmid":"41882248","title":"Assessment of levels spatiotemporal differences and health risks of environmental radioactivity in the soil of Chongqing China.","journal":"Scientific reports"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Bayer Hlthcare","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"2016","aiSummary":"Radium bromatum, also known as radium, is a small molecule drug developed by Bayer Healthcare. Although it was FDA approved in 2016, its target, drug class, and approved indications are unknown. Radium bromatum is currently off-patent, with no active Orange Book patents. As a result, there are no generic manufacturers. Despite its commercial status, key safety considerations are not publicly available.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"BAYER HLTHCARE","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}